Leadership

Michael Wyzga

Chairman

Michael Wyzga has served as a director since October 2013 and as our Chairman since March 2016. Mr. Wyzga is currently the President of MSW Consulting, Inc., a private company focused on strategic consulting for the pharmaceutical and biotechnology industries.

Mr. Wyzga served in various senior management positions at Genzyme Corporation, a biopharmaceutical company that was acquired by Sanofi in 2011, including as Executive Vice President, Finance and Chief Financial Officer. From 2011 to 2013, he was the President and Chief Executive Officer of Radius Health, Inc., during which he was also a member of the Board of Directors.

Mr. Wyzga has extensive experience serving on the Board of Directors of life science companies. He served as a Board member and chair of the audit committee of OncoMed Pharmaceuticals, Inc. from 2013 until its merger with Mereo BioPharma Group plc in 2019. He also served as a Board member of Akebia Therapeutics, Inc., where he chaired the audit committee and served on the compensation committee, and as a member of the Board of Directors of Exact Sciences Corporation, where he was a member of the audit and compensation committees. Mr. Wyzga also previously served as a Board member of Idenix Pharmaceuticals, Inc., Altus Pharmaceuticals, Inc. and Prosensa Holding B.V., or Prosensa. Besides GenSight Biologics, he currently is a member of the Boards of X4 Pharmaceuticals, Mereo BioPharma Group plc and Invivyd, Inc.

Mr. Wyzga received an M.B.A. from Providence College and a B.S. from Suffolk University.

Laurence Rodriguez

Director

Laurence Rodriguez has over 30 years’ experience in the life sciences industry, including 13 years in the rare diseases business at Sanofi. She helped drive the establishment, growth and success of Genzyme in France as a leader in rare diseases, which was capped by the acquisition of the company by Sanofi in 2011. After the acquisition, Laurence held a range of operational and strategic roles, serving in the Executive Committee. As Head of the Rare Diseases & Rare Blood Disorders unit at Sanofi, she oversaw the successful launch of various rare disease products developed or acquired by the Company.

She joined GenSight Biologics in May 2021 as Country Manager and Head of Operations for France and Benelux. She coordinated the early access program in preparation for LUMEVOQ®’s commercialization and created strong relationships based on mutual trust with key stakeholders in the French market. 

She was appointed as CEO by GenSight Biologics’ Board in December 2023 to lead the company’s revitalized strategy. In 2025, she was elected to the Biotech College of the Board of Directors of France Biotech, the trade association of biotechnology firms in France, and in 2026 to the Board of Directors of LEEM, the industry group of pharmaceutical companies operating in France.

Laurence holds a master’s in management and health policy from Sciences Po Paris and a B.Sc. from Paris University. She also completed an Organization Leadership Program at the Harvard Business School.

Maritza McIntyre, Ph.D.

Independent Director

Dr. Maritza McIntyre has served on the Board of Directors since 2019. She is the President of Advanced Therapies Partners, LLC, where she provides strategic regulatory and product development advice to biotech companies, academics and venture capital firms.

She has 20 years of experience in the development, evaluation and regulation of biological and small molecule products within startup biotech firms, the FDA and as a consultant. Through her participation in industry associations, including ASGCT and the Standards Coordinating Body, she continues to contribute to the development of gene therapy regulatory policy.

Dr. McIntyre was a product reviewer and ultimately Branch Chief in the Division of Cellular and Gene Therapies at FDA/CBER, where she was actively involved in policy development and liaison activities to stakeholder groups. She has since worked in senior roles in regulatory affairs and product development at Bavarian Nordic, REGENXBIO, NanoCor Therapeutics and Bamboo Therapeutics. She has also been involved in the preparation of some of the first BLA and MAA submissions for gene therapy products to the FDA and EMA.

Dr. McIntyre received a Ph.D. in Virology from the University of Chicago and graduated magna cum laude with an Honors B.S. in Biology from Wayne State University.

Cédric Moreau

Representing Sofinnova Partners

Cédric Moreau has served on the Board of Directors as the representative of Sofinnova Partners since June 2019, bringing decades of experience in life sciences investment banking. In total, he has managed transactions (IPOs, follow-on offerings and PIPEs) in European healthcare companies totaling around €2 billion in value.

Mr. Moreau joined Sofinnova Partners in June 2018, bringing to the Sofinnova Crossover team his transactional expertise in the biopharma industry, along with an extensive network of Key Opinion Leaders (KOLs), bankers and lawyers. He joined from Oddo BHF, where he was Managing Director and Head of Healthcare in the Corporate Finance department. In 2017, Oddo BHF was top-ranked in the league tables for European biotech equity capital market deals. Prior to this, he was a Director at Bryan Garnier & Co., where he completed several sizeable cross-border transactions. 

Before his corporate finance career, Mr. Moreau spent 10 years as a Healthcare Equity Analyst and was several times EXTEL top-ranked, both individually and as part of a team, at Natixis and Fortis. He was in charge of covering both listed biotech and pharma companies. 

Mr. Moreau holds a master’s degree in economics and post-graduate diploma in finance and taxation from the Sorbonne, as well as a diploma from the Société Française des Analystes Financiers (SFAF).

Simone Seiter, M.D., Ph.D.

Independent Director

Dr. Simone Seiter has been a Senior Partner at Simon-Kucher & Partners, a leading global life sciences commercial strategy consulting practice, since 2020. In 2020, Dr. Seiter also co-founded Priothera, an oncology-focused pre-commercial biotech company based in Ireland, where she now serves as the head of the Clinical and Commercial Advisory Board. 

Prior to joining Simon-Kucher & Partners, Dr. Seiter was a Vice President at IQVIA, based in Frankfurt, Germany, from 2006 to 2019. Before IQVIA, she worked for six years at Capgemini as a consultant.

Dr. Seiter holds an M.D., Ph.D. from the University of Heidelberg and an M.B.A. from the University of Applied Sciences in Neu-Ulm, Germany. She spent two years as a post-doctoral fellow at the National Institutes of Health (U.S.) and worked at the University of Heidelberg and in Homburg, Germany, as a board-certified dermatologist.

Françoise de Craecker

Independent Director

Ms. de Craecker led the EMEA (Europe, Middle East & Africa) region at AveXis, which was acquired by Novartis in 2018. At AveXis, she built from scratch the multi-functional EMEA launch team for ZOLGENSMA®, the first one-shot gene therapy for the treatment of spinal muscular atrophy. She paved the way for approval, distribution, market access and commercialization, working with authorities on innovative funding pathways and early access. She also established the product’s commercial footprint in the main European markets and built a network of distributors in the Middle East and other European countries.

Prior to joining AveXis, Ms. de Craecker led EMEA operations for Raptor Pharmaceuticals (later acquired by Horizon and Chiesi) at the critical phase of a shift from R&D to commercialization of their lead product in cystinosis, followed by the launch of their acquired product in cystic fibrosis. Before that, she was at Shire Human Genetics for 14 years, where she was a member of the team launching the first orphan drug approved in Europe. She subsequently assumed roles with increasing responsibilities and led various strategic and operational teams, locally and globally, based in different European countries and the U.S.

Elsy Boglioli

 Independent Director

Elsy Boglioli became a Board member in 2020. 

She is the founder and CEO of Bio-Up, a healthcare advisory firm supporting companies in strong scale up or transformation phases, mainly in the field of cell and gene therapy. She has far-reaching expertise and a broad network within the pharma and medtech industries.

Before she created Bio-Up, Ms. Boglioli was Executive Vice President and Chief Operating Officer at Cellectis, a French biotechnology company focused on gene editing and its applications in oncology. At Cellectis, she led various strategic and operational functions: strategy, business development, clinical trials program management and manufacturing, with the objective of building in-house capacity. 

Prior to joining Cellectis, Ms. Boglioli worked at the Boston Consulting Group (BCG) for 12 years. She served as Partner and Managing Director in the Paris Office and led BCG’s biotech-focused business in Europe. She worked closely with biotech and pharma companies on topics such as specialty product launch optimization, partnering and M&A.

Ms. Boglioli graduated from the Ecole Polytechnique in Paris, France, and holds a master’s degree in economics and management from the Pompeu Fabra University in Barcelona, Spain. She also holds a degree in immuno-oncology from Institut Gustave Roussy in Paris, France.

Prof. José-Alain Sahel, M.D., Ph.D.

Director

Prof. José-Alain Sahel is an internationally renowned French-American ophthalmologist and scientist whose exceptional academic and hospital career has ranged across France, the U.K. and the U.S.

A graduate of the Faculty of Medicine in Paris (medalist in 1980), he specialized in ophthalmology in Strasbourg, Paris and at Harvard University. From 2001 to 2021, Prof. Sahel led two departments of ophthalmology (at the Quinze-Vingts National Eye Hospital and at the Rothschild Ophthalmology Foundation, both in Paris) and founded the Vision Institute in 2008. The institute has become one of the largest integrated research centers in Europe for vision diseases.

Prof. Sahel was a Professor at Sorbonne Université and also held the Cumberlege Chair of Biomedical Sciences at the Institute of Ophthalmology at University College London. He is currently Distinguished Professor and Chair of the Department of Ophthalmology at the University of Pittsburgh, where he directs the UPMC Vision Institute.

His pioneering work in understanding and treating incurable retinal diseases has led to major advances in gene therapy, optogenetics, artificial retina and neuroprotection, several of which have resulted in first-in-human trials. He is notably the co-discoverer of the cone viability factor (RdCVF), paving the way for new therapeutic strategies to preserve central vision in retinitis pigmentosa and age-related macular degeneration, and he led the first successful clinical applications of optogenetics and of wireless retinal prosthesis.

Prof. Sahel is the author of more than 800 scientific publications, the inventor of numerous patents and the recipient of prestigious awards and distinctions, including election to several academies, the Legion of Honor, the National Order of Merit, the CNRS Innovation Medal, the 2024 Wolf Prize in Medicine and the 2026 ARVO Proctor Medal.

William Monteith

Independent Director

William J. Monteith joined the Board of Directors in 2024, bringing with him over 40 years of experience in both small molecule and large molecule pharmaceutical manufacturing. Over the course of his career, he held positions of increasing responsibility in Operations, Quality and Technical Support. He was directly involved in the site search, design and build-out of six pharmaceutical and biotech facilities.

While at Wyeth and Sandoz, Mr. Monteith oversaw the successful implementation of remediation activities for regulatory actions. He was the General Manager for Dendreon when the approval and commercialization of the first dendritic cell personalized medicine was launched. He later became the Executive Vice President of Dendreon, responsible for the manufacturing supply chain and the launch of Provenge® in Europe.

After the sale of Dendreon to Valeant, Mr. Monteith was appointed Chief Operating Officer at Progenitor Cell Therapy, a CDMO that was eventually acquired by Hitachi Chemical. During his role with Hitachi, he oversaw the expansion of their Allendale, New Jersey, facility as well as the build-out of a cell and gene therapy facility in Yokohama, Japan. Upon leaving Hitachi Chemical Advanced Therapies, Mr. Monteith joined Cellectis as Vice President Manufacturing, North America, where he was responsible for locating a CAR-T manufacturing facility in North America and eventually oversaw the purchase and build-out of a facility in Raleigh, North Carolina. Shortly after the build-out, he was appointed Executive Vice President of Global Operations at Cellectis, responsible for operational departments in both Raleigh and Paris.

Upon leaving Cellectis, Mr. Monteith was named Chief Operating Officer for StrideBio, a research and development company focused on AAV products for rare diseases. There, he was responsible for the build-out of the operations departments and a clinical manufacturing facility. 

Since his retirement, Mr. Monteith has taken the role of Program Director for the North Carolina Life Sciences Biomanufacturing Forum, a trade organization that advocates for life sciences companies that operate in the state. He is also an Executive Advisor at Kymanox, a service provider for the life science industry, and serves on the advisory board for GXP Storage Solution.